The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Hexal
Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim for the prevention of severe neutropenia, in patients with breast cancer receiving myelosuppressive chemotherapy.
 
Andriy Krendyukov
No Relationships to Disclose
 
Nadia Harbeck
Honoraria - Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Celgene; Hexal; Novartis; Pfizer; Roche/Genentech; Sandoz
Research Funding - Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Pedro Gascon
No Relationships to Disclose
 
Sreekanth Gattu
Employment - Hexal
 
Yuhan Li
Employment - Sandoz
 
Kimberly L. Blackwell
Consulting or Advisory Role - Advaxis; Amgen; Amgen; Bayer; Celgene; Coherus Biosciences; Eisai; G1 Therapeutics; Genentech; Incyte; Lilly; Macrogenics; Merck; Novartis; Pfizer; Pierian Biosciences; Puma Biotechnology; Roche; Sandoz; Spectrum Pharmaceuticals
Research Funding - Genentech (Inst); Novartis (Inst); pfizer (Inst)
Travel, Accommodations, Expenses - Advaxis; Amgen; Celgene; Coherus Biosciences; Eisai; Genentech; Lilly; Macrogenics; Merck; Novartis; Pfizer; Pierian Biosciences; Puma Biotechnology; Roche; Sandoz